Abstract
The human epidermal growth factor receptor (HER/ErbB) family consists of four members: HER-1 or epidermal growth factor receptor (EGFR), HER-2, HER-3, and HER-4. These receptors play a crucial role in regulating cell development, growth, and tumorigenesis. The HER/ErbB receptors are involved in the genesis and progression of various human malignancies. Hence, monoclonal antibodies (mAbs) and tyrosine kinase inhibitors targeting the HER signaling pathway have been explored and continuously being developed as therapeutic strategies for cancer. Although these targeted therapies appear to improve progression-free survival (PFS) and overall survival rates in cancers, therapeutically they offer a limited clinical benefit due to relapse, resistance, and toxicity incidences. This chapter highlights the HER receptor signaling pathways and their roles in tumorigenesis, current therapeutic targets, and various challenges of anti-HER therapies including tumor resistance and toxicity. The emerging targets, newer classes of drugs, and strategies in cancer treatment are further discussed.
This is a preview of subscription content, log in via an institution to check access.
References
Adams CW et al (2006) Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55:717–727. https://doi.org/10.1007/s00262-005-0058-x
Agus DB et al (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127–137. https://doi.org/10.1016/S1535-6108(02)00097-1
Aittomäki S, Pesu M (2014) Therapeutic targeting of the JAK/STAT pathway. Basic Clin Pharmacol 114:18–23. https://doi.org/10.1111/bcpt.12164
Amin DN et al (2010) Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med 2:16ra17. https://doi.org/10.1126/scitranslmed.3000389
Amrane K, Querellou S, Schick U, Abgral R, Metges JP (2020) Complete metabolic response assessed by FDG PET/CT to paclitaxel-ramucirumab in patients with metastatic gastroesophageal junction cancer. Clin Nucl Med 45:127–128. https://doi.org/10.1097/rlu.0000000000002882
Andl CD, Mizushima T, Oyama K, Bowser M, Nakagawa H, Rustgi AK (2004) EGFR-induced cell migration is mediated predominantly by the JAK-STAT pathway in primary esophageal keratinocytes. Am J Physiol Gastrointest Liver Physiol 287:G1227–G1237. https://doi.org/10.1152/ajpgi.00253.2004
André F et al (2014) Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15:580–591. https://doi.org/10.1016/S1470-2045(14)70138-X
Anido J, Scaltriti M, Bech Serra JJ, Santiago Josefat B, Todo FR, Baselga J, Arribas J (2006) Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 25:3234–3244. https://doi.org/10.1038/sj.emboj.7601191
Arienti C, Pignatta S, Tesei A (2019) Epidermal growth factor receptor family and its role in gastric cancer. Front Oncol 9:1308. https://doi.org/10.3389/fonc.2019.01308
Arpino G, Ferrero JM, de la Haba-Rodriguez J, Easton V, Schuhmacher C, Restuccia E, Rimawi M (2017) Abstract S3-04: primary analysis of PERTAIN: a randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first-line patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer. Cancer Res 77:S3-04. https://doi.org/10.1158/1538-7445.SABCS16-S3-04
Arpino G et al (2021) Abstract PD3-02: final analysis of PERTAIN: a randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of first-line pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer. Cancer Res 81:PD3-02. https://doi.org/10.1158/1538-7445.SABCS20-PD3-02
Arteaga CL (2001) The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19:32s–40s
Bajaj M, Waterfield MD, Schlessinger J, Taylor WR, Blundell T (1987) On the tertiary structure of the extracellular domains of the epidermal growth factor and insulin receptors. Biochim Biophys Acta 916:220–226. https://doi.org/10.1016/0167-4838(87)90112-9
Bardelli A et al (2013) Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 3:658. https://doi.org/10.1158/2159-8290.CD-12-0558
Baselga J, Averbuch SD (2000) ZD1839 (‘Iressa’) as an anticancer agent. Drugs 60(Suppl 1):33–40; discussion 41–32. https://doi.org/10.2165/00003495-200060001-00004
Baselga J et al (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737–744. https://doi.org/10.1200/jco.1996.14.3.737
Baselga J et al (2011) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109–119. https://doi.org/10.1056/NEJMoa1113216
Baselga J et al (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379:633–640. https://doi.org/10.1016/s0140-6736(11)61847-3
Baselga J, Coleman RE, Cortés J, Janni W (2017) Advances in the management of HER2-positive early breast cancer. Crit Rev Oncol Hematol 119:113–122. https://doi.org/10.1016/j.critrevonc.2017.10.001
Bauer TM et al (2015) A phase 1, open-label study to evaluate the safety and pharmacokinetics of the anti ErbB3 antibody, KTN3379, alone or in combination with targeted therapies in patients with advanced tumors. J Clin Oncol 33:2598. https://doi.org/10.1200/jco.2015.33.15_suppl.2598
Berger MB, Mendrola JM, Lemmon MA (2004) ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett 569:332–336. https://doi.org/10.1016/j.febslet.2004.06.014
Bettegowda C et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224ra24. https://doi.org/10.1126/scitranslmed.3007094
Bonnefoi H et al (2015) Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. Ann Oncol 26:325–332. https://doi.org/10.1093/annonc/mdu551
Bousoik E, Montazeri Aliabadi H (2018) “Do we know Jack” about JAK? A closer look at JAK/STAT signaling pathway. Front Oncol 8:287
Bouyain S, Longo PA, Li S, Ferguson KM, Leahy DJ (2005) The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. Proc Natl Acad Sci U S A 102:15024–15029. https://doi.org/10.1073/pnas.0507591102
Brand TM, Iida M, Wheeler DL (2011) Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther 11:777–792. https://doi.org/10.4161/cbt.11.9.15050
Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr (1999) Stat3 as an oncogene. Cell 98:295–303. https://doi.org/10.1016/s0092-8674(00)81959-5
Cameron D et al (2017) 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389:1195–1205. https://doi.org/10.1016/S0140-6736(16)32616-2
Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E (2012) Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii11–vii19. https://doi.org/10.1093/annonc/mds232
Carraway KL 3rd et al (1994) The erbB3 gene product is a receptor for heregulin. J Biol Chem 269:14303–14306
Chang H, Riese DJ 2nd, Gilbert W, Stern DF, McMahan UJ (1997) Ligands for ErbB-family receptors encoded by a neuregulin-like gene. Nature 387:509–512. https://doi.org/10.1038/387509a0
Chang F et al (2003) Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17:1263–1293. https://doi.org/10.1038/sj.leu.2402945
Cho HS, Leahy DJ (2002) Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297:1330–1333. https://doi.org/10.1126/science.1074611
Christianson TA, Doherty JK, Lin YJ, Ramsey EE, Holmes R, Keenan EJ, Clinton GM (1998) NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 58:5123–5129
Ciardiello F et al (2000) Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6:3739
Cobleigh MA et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–2648. https://doi.org/10.1200/jco.1999.17.9.2639
Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, Baselga J (1999) Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 59:1196–1201
Cohenuram M, Saif MW (2007) Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anti-Cancer Drugs 18:7–15. https://doi.org/10.1097/CAD.0b013e32800feecb
Collins DM, Conlon NT, Kannan S, Verma CS, Eli LD, Lalani AS, Crown J (2019) Preclinical characteristics of the irreversible Pan-HER kinase inhibitor Neratinib compared with Lapatinib: implications for the treatment of HER2-positive and HER2-mutated breast cancer. Cancer 11:737. https://doi.org/10.3390/cancers11060737
Coussens L et al (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132–1139. https://doi.org/10.1126/science.2999974
Cuello M et al (2001) Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61:4892–4900
Davidson M, Starling N (2016) Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives. Onco Targets Ther 9:7235–7245. https://doi.org/10.2147/ott.S100643
Denlinger CS et al (2011) Abstract LB-410: phase I dose escalation study of MM-121, a fully human monoclonal antibody to ErbB3, in patients with advanced solid tumors. Cancer Res 71:LB-410. https://doi.org/10.1158/1538-7445.AM2011-LB-410
Denlinger CS, Keedy VL, Moyo V, MacBeath G, Shapiro GI (2021) Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Investig New Drugs 39:1604–1612. https://doi.org/10.1007/s10637-021-01145-y
Dhritlahre RK, Saneja A (2021) Recent advances in HER2-targeted delivery for cancer therapy. Drug Discov Today 26:1319–1329. https://doi.org/10.1016/j.drudis.2020.12.014
Diaz LA Jr et al (2012) The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486:537–540. https://doi.org/10.1038/nature11219
Diaz LA Jr, Sausen M, Fisher GA, Velculescu VE (2013) Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA. Oncotarget 4:1856–1857. https://doi.org/10.18632/oncotarget.1486
Diéras V et al (2017) Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 18:732–742. https://doi.org/10.1016/S1470-2045(17)30312-1
El Bali M, Bakkach J, Bennani Mechita M (2021) Colorectal cancer: from genetic landscape to targeted therapy. J Oncol 2021:9918116. https://doi.org/10.1155/2021/9918116
Engelman Jeffrey A et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039–1043. https://doi.org/10.1126/science.1141478
Esaki T et al (2015) Abstract C120: phase I study of the safety and tolerability of LJM716 in Japanese patients with advanced solid tumors. Mol Cancer Ther 14:C120. https://doi.org/10.1158/1535-7163.TARG-15-C120
Fabian MA et al (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329–336. https://doi.org/10.1038/nbt1068
Ferguson KM (2008) Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys 37:353–373. https://doi.org/10.1146/annurev.biophys.37.032807.125829
Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA (2003) EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11:507–517. https://doi.org/10.1016/s1097-2765(03)00047-9
Flågeng MH et al (2009) Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. Br J Cancer 101:1253–1260. https://doi.org/10.1038/sj.bjc.6605324
Frolov A et al (2007) ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Cancer Biol Ther 6:548–554. https://doi.org/10.4161/cbt.6.4.3849
Gajria D, Chandarlapaty S (2011) HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 11:263–275. https://doi.org/10.1586/era.10.226
Gan HK et al (2021) A phase I, first-in-human study of GSK2849330, an anti-HER3 monoclonal antibody, in HER3-expressing solid tumors. Oncologist 26:e1844–e1853. https://doi.org/10.1002/onco.13860
Gao L-f, Xu D-q, Wen L-j, Zhang X-y, Shao Y-t, Zhao X-j (2005) Inhibition of STAT3 expression by si RNA suppresses growth and induces apoptosis in laryngeal cancer cells. Acta Pharmacol Sin 26:377–383. https://doi.org/10.1111/j.1745-7254.2005.00053.x
Garg R, Benedetti LG, Abera MB, Wang H, Abba M, Kazanietz MG (2014) Protein kinase C and cancer: what we know and what we do not. Oncogene 33:5225–5237. https://doi.org/10.1038/onc.2013.524
Garrett TP et al (2002) Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110:763–773. https://doi.org/10.1016/s0092-8674(02)00940-6
Garrett TP et al (2003) The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 11:495–505. https://doi.org/10.1016/s1097-2765(03)00048-0
Garrett JT et al (2011) Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A 108:5021–5026. https://doi.org/10.1073/pnas.1016140108
Gelmon KA et al (2015) Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31. J Clin Oncol 33:1574–1583. https://doi.org/10.1200/jco.2014.56.9590
Ghatak S, Lin K, Lou E, Nelson AC (2020) Trastuzumab-Pertuzumab resistance in a case of HER2-del16 expressing colorectal cancer–a case report. Precis Cancer Med 3:21
Giuliano M, Trivedi MV, Schiff R (2013) Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications. Breast Care 8:256–262. https://doi.org/10.1159/000354253
Goehler H et al (2004) A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington’s disease. Mol Cell 15:853–865. https://doi.org/10.1016/j.molcel.2004.09.016
Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1:1311–1318
Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647–1655. https://doi.org/10.1093/emboj/16.7.1647
Gross ME, Shazer RL, Agus DB (2004) Targeting the HER-kinase axis in cancer. Semin Oncol 31:9–20. https://doi.org/10.1053/j.seminoncol.2004.01.005
Gual P, Giordano S, Williams TA, Rocchi S, Van Obberghen E, Comoglio PM (2000) Sustained recruitment of phospholipase C-γ to Gab1 is required for HGF-induced branching tubulogenesis. Oncogene 19:1509–1518. https://doi.org/10.1038/sj.onc.1203514
Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12:9–22. https://doi.org/10.1016/j.ccr.2007.05.008
Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL (2020) ERK/MAPK signalling pathway and tumorigenesis (Review). Exp Ther Med 19:1997–2007. https://doi.org/10.3892/etm.2020.8454
Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL 3rd (1994) Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A 91:8132–8136. https://doi.org/10.1073/pnas.91.17.8132
Gyori D, Chessa T, Hawkins PT, Stephens LR (2017) Class (I) phosphoinositide 3-kinases in the tumor microenvironment. Cancers (Basel) 9(3):24. https://doi.org/10.3390/cancers9030024
Hervent AS, De Keulenaer GW (2012) Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics. Int J Mol Sci 13:12268–12286. https://doi.org/10.3390/ijms131012268
Higashiyama S et al (1997) A novel brain-derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4. J Biochem 122:675–680. https://doi.org/10.1093/oxfordjournals.jbchem.a021806
Hsieh AC, Moasser MM (2007) Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 97:453–457. https://doi.org/10.1038/sj.bjc.6603910
Hubbard SR (1999) Structural analysis of receptor tyrosine kinases. Prog Biophys Mol Biol 71:343–358. https://doi.org/10.1016/s0079-6107(98)00047-9
Humblet Y (2004) Cetuximab: an IgG1 monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. Expert Opin Pharmacother 5:1621–1633. https://doi.org/10.1517/14656566.5.7.1621
Hunter T (2000) Signaling–2000 and beyond. Cell 100:113–127. https://doi.org/10.1016/s0092-8674(00)81688-8
Jacinto E, Hall MN (2003) Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 4:117–126. https://doi.org/10.1038/nrm1018
Jacob W, James I, Hasmann M, Weisser M (2018) Clinical development of HER3-targeting monoclonal antibodies: perils and progress. Cancer Treat Rev 68:111–123. https://doi.org/10.1016/j.ctrv.2018.06.011
Jiang X, Borgesi RA, McKnight NC, Kaur R, Carpenter CL, Balk SP (2007) Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells. J Biol Chem 282:32689–32698. https://doi.org/10.1074/jbc.M703412200
Johnston S et al (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor – positive metastatic breast cancer. J Clin Oncol 27:5538–5546. https://doi.org/10.1200/JCO.2009.23.3734
Kadamur G, Ross EM (2013) Mammalian phospholipase C. Annu Rev Physiol 75:127–154. https://doi.org/10.1146/annurev-physiol-030212-183750
Kani K, Park E, Landgraf R (2005) The extracellular domains of ErbB3 retain high ligand binding affinity at endosome pH and in the locked conformation. Biochemistry 44:15842–15857. https://doi.org/10.1021/bi0515220
Karin M, Hunter T (1995) Transcriptional control by protein phosphorylation: signal transmission from the cell surface to the nucleus. Curr Biol 5:747–757. https://doi.org/10.1016/s0960-9822(95)00151-5
Kaufman B et al (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27:5529–5537. https://doi.org/10.1200/JCO.2008.20.6847
Kawakami H et al (2014) The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget 5:11847–11856. https://doi.org/10.18632/oncotarget.2663
Kim HH, Vijapurkar U, Hellyer NJ, Bravo D, Koland JG (1998) Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. Biochem J 334(Pt 1):189–195. https://doi.org/10.1042/bj3340189
Kim JH, Saito K, Yokoyama S (2002) Chimeric receptor analyses of the interactions of the ectodomains of ErbB-1 with epidermal growth factor and of those of ErbB-4 with neuregulin. Eur J Biochem 269:2323–2329. https://doi.org/10.1046/j.1432-1033.2002.02877.x
Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, Yarden Y (1999) The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A 96:4995–5000. https://doi.org/10.1073/pnas.96.9.4995
Kodack DP et al (2017) The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. Sci Transl Med 9:eaal4682. https://doi.org/10.1126/scitranslmed.aal4682
Kohda D et al (1993) A 40-kDa epidermal growth factor/transforming growth factor alpha-binding domain produced by limited proteolysis of the extracellular domain of the epidermal growth factor receptor. J Biol Chem 268:1976–1981
Kulukian A et al (2020) Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Mol Cancer Ther 19:976–987. https://doi.org/10.1158/1535-7163.Mct-19-0873
Kunigal S, Lakka SS, Sodadasu PK, Estes N, Rao JS (2009) Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer. Int J Oncol 34:1209–1220. https://doi.org/10.3892/ijo_00000249
Kurokawa Y et al (2014) Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer 110:1163–1168. https://doi.org/10.1038/bjc.2014.18
Liang ZW et al (2011) Plasmid-based Stat3 siRNA delivered by hydroxyapatite nanoparticles suppresses mouse prostate tumour growth in vivo. Asian J Androl 13:481–486. https://doi.org/10.1038/aja.2010.167
Linggi B, Carpenter G (2006) ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol 16:649–656. https://doi.org/10.1016/j.tcb.2006.10.008
Liongue C, Ward AC (2013) Evolution of the JAK-STAT pathway. Jakstat 2:e22756. https://doi.org/10.4161/jkst.22756
Lockhart AC et al (2016) Phase 1 evaluation of [64Cu]DOTA-patritumab to assess dosimetry, apparent receptor occupancy, and safety in subjects with advanced solid tumors. Mol Imaging Biol 18:446–453. https://doi.org/10.1007/s11307-015-0912-y
LoRusso P et al (2013) Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 19:3078. https://doi.org/10.1158/1078-0432.CCR-12-3051
Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:1852–1857. https://doi.org/10.1093/jnci/93.24.1852
Maadi H, Nami B, Tong J, Li G, Wang Z (2018) The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2. BMC Cancer 18:238. https://doi.org/10.1186/s12885-018-4143-x
Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912–1934. https://doi.org/10.1126/science.1075762
Margolis B et al (1990) The tyrosine phosphorylated carboxyterminus of the EGF receptor is a binding site for GAP and PLC-gamma. EMBO J 9:4375–4380
Marquardt H, Hunkapiller MW, Hood LE, Twardzik DR, De Larco JE, Stephenson JR, Todaro GJ (1983) Transforming growth factors produced by retrovirus-transformed rodent fibroblasts and human melanoma cells: amino acid sequence homology with epidermal growth factor. Proc Natl Acad Sci U S A 80:4684–4688. https://doi.org/10.1073/pnas.80.15.4684
Martin KA, Blenis J (2002) Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. Adv Cancer Res 86:1–39
Mattoon DR, Lamothe B, Lax I, Schlessinger J (2004) The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway. BMC Biol 2:24. https://doi.org/10.1186/1741-7007-2-24
Mendell J et al (2015) Clinical translation and validation of a predictive biomarker for patritumab, an anti-human epidermal growth factor receptor 3 (HER3) monoclonal antibody, in patients with advanced non-small cell lung cancer. EBioMedicine 2:264–271. https://doi.org/10.1016/j.ebiom.2015.02.005
Mendelsohn J (2001) The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 8:3–9
Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21:2787–2799. https://doi.org/10.1200/JCO.2003.01.504
Meulendijks D et al (2016) First-in-human phase I study of lumretuzumab, a glycoengineered humanized anti-HER3 monoclonal antibody, in patients with metastatic or advanced HER3-positive solid tumors. Clin Cancer Res 22:877. https://doi.org/10.1158/1078-0432.CCR-15-1683
Miklossy G, Hilliard TS, Turkson J (2013) Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov 12:611–629. https://doi.org/10.1038/nrd4088
Miller TW, Rexer BN, Garrett JT, Arteaga CL (2011) Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 13:224. https://doi.org/10.1186/bcr3039
Misale S et al (2014a) Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med 6:224ra226. https://doi.org/10.1126/scitranslmed.3007947
Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A (2014b) Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 4:1269. https://doi.org/10.1158/2159-8290.CD-14-0462
Mishra R, Patel H, Alanazi S, Yuan L, Garrett JT (2018) HER3 signaling and targeted therapy in cancer. Oncol Rev 12:355. https://doi.org/10.4081/oncol.2018.355
Moasser MM (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26:6469–6487. https://doi.org/10.1038/sj.onc.1210477
Mohan S et al (2014) Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet 10:e1004271. https://doi.org/10.1371/journal.pgen.1004271
Molina JR, Adjei AA (2006) The Ras/Raf/MAPK pathway. J Thorac Oncol 1:7–9
Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J (2001) Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61:4744–4749
Molina MA et al (2002) NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 8:347–353
Montagut C et al (2012) Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 18:221–223. https://doi.org/10.1038/nm.2609
Monteiro Ide P, Madureira P, de Vasconscelos A, Pozza DH, de Mello RA (2015) Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies. Pharmacogenomics 16:257–271. https://doi.org/10.2217/pgs.14.133
Moulder SL et al (2017) Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2+-advanced solid tumors, with an expansion cohort in HER2+ metastatic breast cancer (MBC). Clin Cancer Res 23:3529. https://doi.org/10.1158/1078-0432.CCR-16-1496
Muta Y, Matsuda M, Imajo M (2019) Divergent dynamics and functions of ERK MAP kinase signaling in development, homeostasis and cancer: lessons from fluorescent bioimaging. Cancers (Basel) 11(4):513. https://doi.org/10.3390/cancers11040513
Nagata Y et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117–127. https://doi.org/10.1016/j.ccr.2004.06.022
Nagumo Y, Faratian D, Mullen P, Harrison DJ, Hasmann M, Langdon SP (2009) Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity. Mol Cancer Res 7:1563. https://doi.org/10.1158/1541-7786.MCR-09-0101
Nahta R (2012) Molecular mechanisms of Trastuzumab-based treatment in HER2-overexpressing breast cancer. ISRN Oncol 2012:428062. https://doi.org/10.5402/2012/428062
Nahta R, Esteva FJ (2006) HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8:215. https://doi.org/10.1186/bcr1612
Nahta R, O’Regan RM (2012) Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast Cancer Res Treat 135:39–48. https://doi.org/10.1007/s10549-012-2067-8
Nahta R, Hung MC, Esteva FJ (2004) The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64:2343–2346. https://doi.org/10.1158/0008-5472.can-03-3856
Nami B, Maadi H, Wang Z (2018) Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer. Cancers (Basel) 10(10):342. https://doi.org/10.3390/cancers10100342
Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ (2009) Trastuzumab-induced HER reprogramming in “resistant” breast carcinoma cells. Cancer Res 69:2191–2194. https://doi.org/10.1158/0008-5472.Can-08-1056
Nishizuka Y (1995) Protein kinase C and lipid signaling for sustained cellular responses. FASEB J 9:484–496. https://doi.org/10.1096/fasebj.9.7.7737456
Niu G et al (2005) Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 25:7432–7440. https://doi.org/10.1128/MCB.25.17.7432-7440.2005
Ocaña A, Pandiella A (2013) Targeting HER receptors in cancer. Curr Pharm Des 19:808–817. https://doi.org/10.2174/138161213804547303
Ogiso H et al (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110:775–787. https://doi.org/10.1016/s0092-8674(02)00963-7
Ohashi K et al (2012) Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A 109:E2127. https://doi.org/10.1073/pnas.1203530109
Ohno S, Nishizuka Y (2002) Protein kinase C isotypes and their specific functions: prologue. J Biochem 132:509–511
Olayioye MA, Graus-Porta D, Beerli RR, Rohrer J, Gay B, Hynes NE (1998) ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol 18:5042–5051. https://doi.org/10.1128/mcb.18.9.5042
O’Shea JJ, Gadina M, Schreiber RD (2002) Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109(Suppl):S121–S131. https://doi.org/10.1016/s0092-8674(02)00701-8
Papadopoulos KP, Moore KN, Lush R, Desai M, Mahmood S, Beckman RA, Mendell-Harary J (2015) Pharmacokinetics, safety, and tolerability of a new patritumab formulation in patients with advanced, refractory solid tumors. J Clin Oncol 33:e14026. https://doi.org/10.1200/jco.2015.33.15_suppl.e14026
Paz-Arez L et al (2017) P3.02b-045 patritumab plus erlotinib in EGFR wild-type advanced nonsmall cell lung cancer (NSCLC): part a Results of HER3-lung study: topic: EGFR clinical. J Thorac Oncol 12:S1214–S1215. https://doi.org/10.1016/j.jtho.2016.11.1712
Perez EA et al (2017) Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: primary results from the phase III MARIANNE study. J Clin Oncol 35:141–148. https://doi.org/10.1200/JCO.2016.67.4887
Petricevic B et al (2013) Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J Transl Med 11:307. https://doi.org/10.1186/1479-5876-11-307
Pinkas-Kramarski R et al (1998) ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network. Mol Cell Biol 18:6090–6101. https://doi.org/10.1128/mcb.18.10.6090
Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA Jr (2002) ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 29:37–46. https://doi.org/10.1053/sonc.2002.31521
Rawlings JS, Rosler KM, Harrison DA (2004) The JAK/STAT signaling pathway. J Cell Sci 117:1281–1283. https://doi.org/10.1242/jcs.00963
Reschke M et al (2008) HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 14:5188–5197. https://doi.org/10.1158/1078-0432.Ccr-08-0186
Reynolds KL et al (2014) A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer. J Clin Oncol 32:2517–2517. https://doi.org/10.1200/jco.2014.32.15_suppl.2517
Reynolds KL et al (2017) A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer 17:646. https://doi.org/10.1186/s12885-017-3641-6
Rimawi M et al (2018) First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2–positive and hormone receptor–positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol 36:2826–2835. https://doi.org/10.1200/JCO.2017.76.7863
Rosenzweig SA (2018) Acquired resistance to drugs targeting tyrosine kinases. Adv Cancer Res 138:71–98. https://doi.org/10.1016/bs.acr.2018.02.003
Rotin D et al (1992) SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase C gamma. EMBO J 11:559–567. https://doi.org/10.1002/j.1460-2075.1992.tb05087.x
Rubin I, Yarden Y (2001) The basic biology of HER2. Ann Oncol 12(Suppl 1):S3–S8. https://doi.org/10.1093/annonc/12.suppl_1.s3
Sarantopoulos J et al (2014) First-in-human phase 1 dose-escalation study of AV-203, a monoclonal antibody against ERBB3, in patients with metastatic or advanced solid tumors. J Clin Oncol 32:11113. https://doi.org/10.1200/jco.2014.32.15_suppl.11113
Scaltriti M et al (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99:628–638. https://doi.org/10.1093/jnci/djk134
Schettini F et al (2021) T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study. ESMO open 6:100099. https://doi.org/10.1016/j.esmoop.2021.100099
Schlam I, Swain SM (2021) HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now. Breast Cancer 7:56. https://doi.org/10.1038/s41523-021-00265-1
Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211–225. https://doi.org/10.1016/s0092-8674(00)00114-8
Schulze WX, Deng L, Mann M (2005) Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol 1:2005.0008. https://doi.org/10.1038/msb4100012
Shi Y et al (2015) Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages. J Immunol 194:4379–4386. https://doi.org/10.4049/jimmunol.1402891
Shing Y, Christofori G, Hanahan D, Ono Y, Sasada R, Igarashi K, Folkman J (1993) Betacellulin: a mitogen from pancreatic beta cell tumors. Science 259:1604–1607. https://doi.org/10.1126/science.8456283
Shoyab M, McDonald VL, Bradley JG, Todaro GJ (1988) Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc Natl Acad Sci U S A 85:6528–6532. https://doi.org/10.1073/pnas.85.17.6528
Sierke SL, Cheng K, Kim HH, Koland JG (1997) Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem J 322(Pt 3):757–763. https://doi.org/10.1042/bj3220757
Soltoff SP, Cantley LC (1996) p120cbl is a cytosolic adapter protein that associates with phosphoinositide 3-kinase in response to epidermal growth factor in PC12 and other cells. J Biol Chem 271:563–567. https://doi.org/10.1074/jbc.271.1.563
Stuhlmiller TJ et al (2015) Inhibition of Lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family Bromodomains. Cell Rep 11:390–404. https://doi.org/10.1016/j.celrep.2015.03.037
Suenaga A et al (2005) Novel mechanism of interaction of p85 subunit of phosphatidylinositol 3-kinase and ErbB3 receptor-derived phosphotyrosyl peptides. J Biol Chem 280:1321–1326. https://doi.org/10.1074/jbc.M410436200
Suzuki T, K-Tsuzuku J, Ajima R, Nakamura T, Yoshida Y, Yamamoto T (2002) Phosphorylation of three regulatory serines of Tob by Erk1 and Erk2 is required for Ras-mediated cell proliferation and transformation. Genes Dev 16:1356–1370. https://doi.org/10.1101/gad.962802
Thomas F et al (2009) Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur J Cancer 45:2316–2323. https://doi.org/10.1016/j.ejca.2009.05.007
Trevino JG et al (2006) Src activation of Stat3 is an independent requirement from NF-kappaB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells. Angiogenesis 9:101–110. https://doi.org/10.1007/s10456-006-9038-9
Tzahar E et al (1996) A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276–5287. https://doi.org/10.1128/mcb.16.10.5276
Ullrich A et al (1984) Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309:418–425. https://doi.org/10.1038/309418a0
van der Horst EH, Murgia M, Treder M, Ullrich A (2005) Anti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies. Int J Cancer 115:519–527. https://doi.org/10.1002/ijc.20867
Verma N, Davies A, Long A, Kelleher D, Volkov Y (2010) STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL. Cell Mol Biol Lett 15:342–355. https://doi.org/10.2478/s11658-010-0008-2
Verma S et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–1791. https://doi.org/10.1056/NEJMoa1209124
Vigneron A, Gamelin E, Coqueret O (2008) The EGFR-STAT3 oncogenic pathway up-regulates the Eme1 endonuclease to reduce DNA damage after topoisomerase I inhibition. Cancer Res 68:815–825. https://doi.org/10.1158/0008-5472.Can-07-5115
Vogel CL et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726. https://doi.org/10.1200/jco.2002.20.3.719
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW (2013) Cancer genome landscapes. Science 339:1546. https://doi.org/10.1126/science.1235122
Wahdan-Alaswad R, Liu B, Thor AD (2020) Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem. Cancer Drug Resist 3:179–198. https://doi.org/10.20517/cdr.2019.92
Wakui H, Yamamoto N, Nakamichi S, Tamura Y, Nokihara H, Yamada Y, Tamura T (2014) Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 73:511–516. https://doi.org/10.1007/s00280-014-2375-2
Wang CW, Klionsky DJ (2003) The molecular mechanism of autophagy. Mol Med 9:65–76
Wang T et al (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10:48–54. https://doi.org/10.1038/nm976
Ward WH, Cook PN, Slater AM, Davies DH, Holdgate GA, Green LR (1994) Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem Pharmacol 48:659–666. https://doi.org/10.1016/0006-2952(94)90042-6
Ward CW, Hoyne PA, Flegg RH (1995) Insulin and epidermal growth factor receptors contain the cysteine repeat motif found in the tumor necrosis factor receptor. Proteins 22:141–153. https://doi.org/10.1002/prot.340220207
Ward CW, Gough KH, Rashke M, Wan SS, Tribbick G, Wang J (1996) Systematic mapping of potential binding sites for Shc and Grb2 SH2 domains on insulin receptor substrate-1 and the receptors for insulin, epidermal growth factor, platelet-derived growth factor, and fibroblast growth factor. J Biol Chem 271:5603–5609. https://doi.org/10.1074/jbc.271.10.5603
Wieduwilt MJ, Moasser MM (2008) The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 65:1566–1584. https://doi.org/10.1007/s00018-008-7440-8
Xia L et al (2002) Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. J Biol Chem 277:30716–30723. https://doi.org/10.1074/jbc.M202823200
Xia W et al (2006) A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A 103:7795–7800. https://doi.org/10.1073/pnas.0602468103
Xu S, Robbins D, Frost J, Dang A, Lange-Carter C, Cobb MH (1995) MEKK1 phosphorylates MEK1 and MEK2 but does not cause activation of mitogen-activated protein kinase. Proc Natl Acad Sci U S A 92:6808–6812. https://doi.org/10.1073/pnas.92.15.6808
Xu F, Na L, Li Y, Chen L (2020) Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours. Cell Biosci 10:54. https://doi.org/10.1186/s13578-020-00416-0
Yang Y-M, Hong P, Xu WW, He Q-Y, Li B (2020) Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther 5:229. https://doi.org/10.1038/s41392-020-00323-3
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137. https://doi.org/10.1038/35052073
Yonesaka K (2021) HER2-/HER3-targeting antibody-drug conjugates for treating lung and colorectal cancers resistant to EGFR inhibitors. Cancers 13:1047. https://doi.org/10.3390/cancers13051047
Yonesaka K et al (2016) Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib. Oncogene 35:878–886. https://doi.org/10.1038/onc.2015.142
Yonesaka K, Hirotani K, von Pawel J, Dediu M, Chen S, Copigneaux C, Nakagawa K (2017) Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer. Lung Cancer 105:1–6. https://doi.org/10.1016/j.lungcan.2016.12.018
Yoon YK et al (2009) Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol Cancer Ther 8:2526–2536. https://doi.org/10.1158/1535-7163.Mct-09-0300
Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, Jove R (1995) Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269:81–83. https://doi.org/10.1126/science.7541555
Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7:41–51. https://doi.org/10.1038/nri1995
Yu HA et al (2013) Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19:2240–2247. https://doi.org/10.1158/1078-0432.Ccr-12-2246
Yudushkin I (2019) Getting the Akt together: guiding intracellular Akt activity by PI3K. Biomol Ther 9(2):67. https://doi.org/10.3390/biom9020067
Zhang N, Chang Y, Rios A, An Z (2016a) HER3/ErbB3, an emerging cancer therapeutic target. Acta Biochim Biophys Sin Shanghai 48:39–48. https://doi.org/10.1093/abbs/gmv103
Zhang N, Zeng Y, Du W, Zhu J, Shen D, Liu Z, Huang JA (2016b) The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. Int J Oncol 49:1360–1368. https://doi.org/10.3892/ijo.2016.3632
Zhong Z, Wen Z, Darnell JE Jr (1994) Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264:95–98. https://doi.org/10.1126/science.8140422
Acknowledgments
The main author would like to acknowledge the FRGS Grant (Kementerian Pelajaran Tinggi Malaysia) (FRGS/1/2018/SKK08/USM/02/13) and Smartfund Challenge Grant (MOSTI) for the financial assistance. Figures were created with BioRender.com (paid licence).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer Nature Switzerland AG
About this entry
Cite this entry
Tan, M.L., Yeap, J.W., Matawali, A. (2023). HER Receptor, Current, and Emerging Therapeutic Targets. In: Rezaei, N. (eds) Handbook of Cancer and Immunology. Springer, Cham. https://doi.org/10.1007/978-3-030-80962-1_258-1
Download citation
DOI: https://doi.org/10.1007/978-3-030-80962-1_258-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-80962-1
Online ISBN: 978-3-030-80962-1
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences